Sentinel Node Biopsy in Endometrial Cancer (ENDO-3)

A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer

Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with specific equipment & surgical dissection of the lymph node in which the dye first becomes visible. Despite this promising proposition & similar to a lymph node dissection, the value to patients, cost effectiveness & potential harms (e.g. lymphedema) of SNB compared to no-node dissection in EC has never been established. Aim: determine the value of SNB for patients, the healthcare system and exclude detriment to patients using a randomised approach 1:1. Stage 1 - 444 patients. Stage 2 additional 316 patients.

Primary Outcome Stage 1:

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

Primary Outcome Stage 2:

Treatment non-inferiority as evaluated by disease-free survival status at 4.5 years post-surgery, as measured by the time interval between the date of randomisation and date of first recurrence. Confirmation of recurrent disease will be ascertained through clinical assessment, radiological work-up and/or histological results.

Study Overview

• Status: Recruiting
• Conditions: Surgery; Sentinel Lymph Node; Endometrial Cancer Stage I
• Intervention / Treatment: Procedure: TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted; Procedure: TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted

Detailed Description

Hypothesis: The primary hypothesis is that SNB will not cause detriment to patients (lymphoedema, morbidity, loss of quality of life) and not increase costs compared to patients without a retroperitoneal node dissection. The secondary hypothesis is that disease-free survival in patients without retroperitoneal node dissection is not inferior to those receiving SNB.

Aims: To determine the value of SNB for patients, the healthcare system and to exclude detriment to patients.

Objectives:

Primary Stage 1:

To determine the recovery of participants (defined as incidence of adverse events, lower limb lymphoedema and health-related QOL) and to the healthcare system (cost) of Sentinel Node Biopsy (SNB) for the surgical treatment of endometrial cancer.

Primary Stage 2:

Compare disease-free survival at 4.5 years for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection.

Secondary:

• Compare patterns of recurrence and overall survival (OS) between the groups
• Determine the cost-effectiveness of SNB
• Compare Patient Reported Outcomes (PROMS) between the groups at 12 months from surgery
• Compare Health Related Quality of Life (HRQL) and Fear of Recurrence between the groups at 12 months from surgery
• Compare perioperative outcomes (duration of surgery, length of hospital stay, intraoperative blood loss, blood transfusion requirements) and the incidence of intra- and postoperative adverse events within 12 months from surgery between the groups
• Compare lower limb lymphoedema at 12 months after surgery
• Compare the need for postoperative (adjuvant) treatments between groups
• Determine the impact of body composition and frailty on survival, quality of life, lymphoedema, peri-, intra- and postoperative outcomes
• Compare follow-up strategies (clinical vs symptom checklist)
• Translational Research - Trans-ENDO 3 - biobanking strategy - Compare the Molecular profile at 12 months from surgery between the groups

• Study Type: Interventional
• Enrollment (Estimated): 760
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
• Study Contact Backup: Name: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au

Study Locations

• Australia
  • New South Wales
    • Camperdown, New South Wales, Australia, 2050
      • Recruiting
      • Chris O'Brien Lifehouse
      • Contact: Rhonda Farrell, MD; Email: rhondafarrell@mac.com
      • Principal Investigator: Rhonda Farrell, MD
      • Contact: Sadaf Kalam; Email: sadaf.kalam@lh.org.au
    • Kogarah, New South Wales, Australia, 2217
      • Not yet recruiting
      • St George Hospital
      • Contact: Michael Burling; Email: michael.burling@health.nsw.gov.au
      • Principal Investigator: Michael Burling
  • Queensland
    • Auchenflower, Queensland, Australia, 4066
      • Recruiting
      • The Wesley Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61 7 3346 5073; Email: sara.baniahmadi@health.qld.gov.au
      • Principal Investigator: Andrea Garrett, MD
      • Contact: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au
      • Sub-Investigator: Rhett Morton, MD
    • Buderim, Queensland, Australia, 4556
      • Recruiting
      • Buderim Private Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
      • Principal Investigator: Andreas Obermair, MD
      • Contact: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au
    • Douglas, Queensland, Australia, 4814
      • Not yet recruiting
      • Townsville Hospital
      • Contact: Greet Hoet, MD; Phone Number: + 61 7 4433 3622; Email: Greet.Hoet@health.qld.gov.au
      • Principal Investigator: Greet Hoet, MD
      • Contact: Vanessa Behan, BSN; Phone Number: + 61 7 3346 5590; Email: endo3trial@uq.edu.au
    • Everton Park, Queensland, Australia, 4053
      • Recruiting
      • North West Private Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
      • Contact: Vanessa Behan; Phone Number: 0733465590; Email: endo3trial@uq.edu.au
      • Principal Investigator: Piksi Singh, MD
    • Herston, Queensland, Australia, 4029
      • Recruiting
      • Royal Brisbane and Women'S Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
      • Principal Investigator: Andrea Garrett, MD
      • Sub-Investigator: Andreas Obermair, MD
      • Sub-Investigator: Russell Land, MD
      • Sub-Investigator: Piksi Singh, MD
      • Contact: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au
      • Sub-Investigator: Rhett Morton, MD
      • Sub-Investigator: Shaun McGrath, MD
    • South Brisbane, Queensland, Australia, 4101
      • Recruiting
      • Mater Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
      • Principal Investigator: Lewis Perrin, MD
      • Sub-Investigator: Naven Chetty, MD
      • Sub-Investigator: Nisha Jagasia, MD
      • Sub-Investigator: Nimithri Cabraal, MD
      • Contact: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au
      • Sub-Investigator: Rhett Morton, MD
      • Sub-Investigator: Shaun McGrath, MD
    • Southport, Queensland, Australia, 4215
      • Not yet recruiting
      • Gold Coast University Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
      • Contact: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au
      • Principal Investigator: Elizabeth Goulding, MD
    • Spring Hill, Queensland, Australia, 4000
      • Recruiting
      • St Andrews War Memorial Hospital
      • Contact: Sara Baniahmadi; Phone Number: +61733465073; Email: sara.baniahmadi@health.qld.gov.au
      • Principal Investigator: Andreas Obermair, MD
      • Contact: Vanessa Behan, BSN; Phone Number: +61 7 3346 5590; Email: endo3trial@uq.edu.au
  • Tasmania
    • Hobart, Tasmania, Australia, 7000
      • Not yet recruiting
      • Royal Hobart Hospital
      • Contact: Nicole Krzys, MD; Email: nicolekrzys@hotmail.com
      • Principal Investigator: Nicole Krzys, MD
  • Victoria
    • Heidelberg, Victoria, Australia, 3084
      • Not yet recruiting
      • Mercy Hospital for Women
      • Contact: Adam Pendlebury, MD; Email: cgo@dradampendlebury.com.au
      • Principal Investigator: Adam Pendlebury
    • Parkville, Victoria, Australia, 3052
      • Recruiting
      • Royal Women's Hospital
      • Contact: Orla McNally, MD; Email: Orla.McNally@thewomens.org.au
      • Principal Investigator: Orla McNally, MD
      • Sub-Investigator: Deborah Neesham, MD
      • Contact: Estefania Vicario; Email: estefania.vicario@thewomens.org.au
• Brazil
  • Sao Paulo
    • São José Do Rio Preto, Sao Paulo, Brazil, 15090-000
      • Not yet recruiting
      • Hospital de Base
      • Contact: Guilherme Accorsi, MD; Email: dr.guilhermeaccorsi@gmail.com
      • Principal Investigator: Guilherme Accorsi, MD
• India
  • Delhi
    • Kolkata, Delhi, India
      • Not yet recruiting
      • Tata Medical Center
      • Contact: Jagannath Mishra, MD; Email: jagannath.mishra@tmckolkata.com
      • Principal Investigator: Jagannath Mishra, MD
• Singapore
  • NUH Zone B
    • Singapore, NUH Zone B, Singapore, 119074
      • Not yet recruiting
      • National University Hospital and National University Cancer Institute
      • Contact: Joseph Ng Soon Yau, MD; Email: obgnsyj@nus.edu.sg
      • Contact: Pearl S Tong, MD; Email: pearl_sy_tong@nuhs.edu.sg
      • Principal Investigator: Joseph Ng Soon Yau, MD
      • Sub-Investigator: Pearl S Tong, MD
      • Sub-Investigator: Jeffrey lowe, MD
• United States
  • Texas
    • Houston, Texas, United States, 77030
      • Not yet recruiting
      • Houston Methodist Hospital
      • Contact: Jaya Kamath; Phone Number: 713-441-6616; Email: jskamath@houstonmethodist.org
      • Contact: Konny Fong; Phone Number: 346.238.5815; Email: klchanfong@houstonmethodist.org
      • Principal Investigator: Behrouz Zand, MD
      • Sub-Investigator: Tarrik Zaid, MD
      • Sub-Investigator: Aparna Kamat, MD
      • Sub-Investigator: Anne Alaniz, MD
      • Sub-Investigator: Anju Suri, MD
      • Sub-Investigator: Pedro Ramirez, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour);
2. Clinically stage I disease (disease confined to body of uterus);
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
4. Signed written informed consent;
5. Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning)
6. All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease
7. Myometrial Invasion on MRI of not more than 50%. (Only if participant is <45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries).
8. Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause.

Exclusion Criteria:

1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging.
2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (>1 cm) on medical imaging;
3. Estimated life expectancy of less than 6 months;
4. Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy;
5. Patients who have previously received radiation treatment to the pelvis
6. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
7. Patient compliance and geographic proximity that do not allow adequate follow-up;
8. Patients with allergy to Indocyanine Green (ICG)
9. Patients who have had previous retroperitoneal surgery
10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy)
11. Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu
12. Uterine perforation during endometrial tissue sampling

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TH BSO with SNB; Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.	Procedure: TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted; Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the "sentinel node". These one or two nodes are thought to be first involved with cancer spread.
Active Comparator: TH BSO without retroperitoneal node dissection; Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.	Procedure: TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted; Removal of uterus, tubes and ovaries without retroperitoneal node dissection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stage 1: Return to usual activities	Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.	12 months from surgery
Stage 2: Disease Free Survival	Compare disease-free survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection	4.5 years from surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cost Effectiveness using QALYs using EuroQoL-5D (EQ-5D) Questionnaire	An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. We will also measure the quality-adjusted life years (QALYs) gained with the intervention and use this to undertake a cost-utility analysis. The QALY calculations will be based on health status measures for trial participants, with valuations of changes in health status and quality of life based on the EQ-5D	12 months from surgery
Cost Effectiveness measuring Intervention costs	An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.	12 months from surgery
Cost Effectiveness measuring GP and specialist consultations	An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.	12 months from surgery
Cost Effectiveness measuring radiology and imaging requirements	An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.	12 months from surgery
Cost Effectiveness measuring prescriptions and over the counter medicine requirements	An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.	12 months from surgery
Cost Effectiveness measuring community and health service requirements and days off work and informal care required by family and friends using a combination of the Health Services Questionnaire and clinical files	An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.	12 months from surgery
Cost Effectiveness: direct costs using a bottom-up approach by recording the volume of resource use in both groups of the trial, and then applying a unit cost to each component	Direct costs wukk be ibtained for smaples of participants, stratified by hospital, operation and outcome to assess the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.	12 months from surgery
Perioperative Outcomes: Adverse Events	Compare perioperative outcomes and the incidence of intra- and postoperative adverse events within 12 months from surgery between groups using Common Terminology Criteria for Adverse Events (CTCAE version 5)	12 months from surgery
Perioperative Outcomes: Length of Surgery	Compare the length of surgery between the two groups. This will be recorded in hh:mm on the surgery form.	At time of surgery
Perioperative Outcomes: Blood Loss during Surgery	Compare the blood loss between the two groups during surgery. This will be recorded in ml.	At time of surgery
Perioperative Outcomes: Blood Transfusion Requirements during Surgery	Compare the blood transfusion requirements between the two groups. This will be recorded in units and recorded on the Surgery Form and the Concomitant Medication Form.	At time of surgery
Perioperative Outcomes: Length of Hospital Stay	Compare the length of hospital stay between the two groups. The duration will be measured in days. Date of surgery being day 0.	At time of discharge from hospital following surgery
Health Related Quality of Life and Fear of Recurrence	Change in Quality of Life using Functional Assessment of Cancer General (FACT-EN), Fear of Recurrence and PROMS between baseline and 1 year after surgery	12 months from surgery
Incidence of Lymphedema	Compare lower limb lymphedema between groups	12 months from surgery
Adjuvant Treatment Requirements	Compare the need for postoperative (adjuvant) treatments between groups and evaluate the impact of SNB on clinical decisions regarding adjuvant treatment. Any chemotherapy or radiation therapy required will be recorded on specific chemotherapy or radiation forms. Chemotherapy will be recorded in mg received and number of doses required including start/end dates. Radiation treatment received will be recorded as total dose of Gy and how many fractions, including start and end dates.	12 months from surgery
Value of Molecular Biomarkers	Translational Research - Compare the Molecular profile of Germline DNA at 12 months from surgery between the groups	12 months from surgery
Value of Molecular Biomarkers	Translational Research - Compare the Molecular profile of Circulating Tumour DNA at 12 months from surgery between the groups	12 months from surgery
Value of Molecular Biomarkers	Translational Research - Compare the Molecular profile of Plasma at 12 months from surgery between the groups	12 months from surgery
Value of Molecular Biomarkers	Translational Research - Compare the Molecular profile of Serum at 12 months from surgery between the groups	12 months from surgery
Overall Survival	Compare overall survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection	4.5 years from surgery
Patterns of Recurrence - date and localization of 1st recurrence	Date and localization of 1st recurrence as confirmed histologically and/or radiologically - Compare these patterns of recurrences between the groups. These will also be adjudicated by an independent committee to ensure accuracy of documented recurrence	4.5 years from surgery
Impact of body composition (sarcopenia) on surgical complications, recovery and overall survival	Body mass measures are practical & sensitive for predicting health risks & outcomes. Sarcopenia is defined as loss of skeletal muscle mass & strength. It's been found to be associated with procedure-related morbidity, survival in cancer patients and increased use of healthcare. The concurrent appearance of low muscle mass with high adiposity (sarcopenic obesity) is common in people with chronic diseases. The trial will determine the role sarcopenia has on participants pre-operatively (via CT images & Bioimpedance Spectroscopy (BIS - if available at site) & postoperatively using the BIS in regard to survival in gynaecological malignancies, if it is a predictive factor for treatment adverse events & participants tolerability of treatment & compare diagnostic methods to determine medical fitness for surgery. BIS sends non-detectable electrical currents, at a range of frequencies through the body allowing precise measurement & analysis of impedance to currents by extracellular fluid	4.5 years from surgery
Impact of frailty on surgical complications, recovery and overall survival	It has been reported consistently that frailty has a significant impact on the occurrence of adverse postoperative outcomes. Therefore, measuring frailty is important to estimate risks, determine the best treatment options, and to aid diagnosis and care planning. Frailty will be measured prior to surgery suing the validated tool - Frailty Phenotype. This may determine the impact frailty has on survival, quality of life, lymphedema, peri-, intra- and postoperative outcomes	4.5 years from surgery
Follow-Up Strategies	Current institutional & clinical guidelines suggest patients need to be seen at regular follow up visits. The risk of developing a recurrence is higher within the initial period after surgery & the majority of recurrences develop within those first 3 years. Participants will ideally be seen 3 monthly for the first 3 years & 6 monthly until 4.5 years. The objective of follow up is that local recurrences from endometrial cancer are potentially curable. It helps to diagnose local recurrences as early as possible so that they are amenable for curative or effective palliative management. We will compare these clinical findings to a symptom checklist that will be completed by participants every 3 months from surgery until 4.5 years. This records patient reported symptoms that may indicate a recurrence. Comparing these findings should determine effective follow up strategies for this group of patients.	4.5 years from surgery
Value of Molecular Biomarkers	Translational Research - Compare Molecular profile from surgery between the groups that require adjuvant therapy for 24 months.	24 months from surgery

Collaborators and Investigators

• Sponsor: Queensland Centre for Gynaecological Cancer
• Collaborators: The University of Queensland
• Investigators: Study Chair: Andreas Obermiar, MD, Director, Queensland Centre for Gynaecological Cancer Research

Publications and helpful links

General Publications

• Obermair A, Nicklin J, Gebski V, Hayes SC, Graves N, Mileshkin L, Lin MY, Beale P, Baxter E, Robledo K, Salomon C, Hanna GB, Janda M. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020. Int J Gynecol Cancer. 2021 Dec;31(12):1595-1601. doi: 10.1136/ijgc-2021-003029. Epub 2021 Nov 2.

Study record dates

Study Major Dates

• Study Start (Actual): January 18, 2021
• Primary Completion (Estimated): January 1, 2031
• Study Completion (Estimated): January 1, 2031

Study Registration Dates

• First Submitted: August 26, 2019
• First Submitted That Met QC Criteria: August 27, 2019
• First Posted (Actual): August 29, 2019

Study Record Updates

• Last Update Posted (Actual): March 26, 2024
• Last Update Submitted That Met QC Criteria: March 24, 2024
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: sentinel node biopsy; uterine cancer
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Endometrial Neoplasms
• Other Study ID Numbers: ENDO-3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No